Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Precedex · 1 trial · 1 indication
| Name | Type | Description |
|---|---|---|
| Precedex | DRUG | Subjects randomized to the comparison group will receive a standardized general anesthetic. Anesthesia will be induced with propofol 1.5 ? 2.5 mg/kg, rocuronium 0.6 mg/kg, and sufentanil 0.1 ? 1mcg/kg. Anesthesia will be maintained with an infusion with propofol 25 -200 mcg/kg/min, sufentanil 0.0025 - 0.03 mcg/kg/min, and zemuron as needed. For the Precedex group the drug will be infused at 0.3-0.7 mcg/kg/hr. Blood pressure will be maintained within 10% of baseline prior to opening of the dura, subsequently to be maintained between a systolic of 100 ? 130 mmHg. Hypertension will be managed with standardized amounts of labetalol and nicardipine. Morphine will be titrated as needed to a maximum of 0.05mcg/kg at the conclusion of case. Hemodynamic data and emergence evaluations will be collected in the operating room, pre-induction until the end of anesthesia and discharge from the operating room. There will be no further follow up. |
| Propofol | DRUG | evaulation of propofol for emergence from anesthesia |
Precedex is a small molecule being studied for use in craniotomy surgery. It has been evaluated in a Phase 3 clinical trial comparing it to propofol for emergence and recovery in patients undergoing this procedure. The trial was completed with 15 participants.
Precedex is a small molecule, but its specific molecular target has not been disclosed in the available information. The drug is being investigated for its effects on emergence and recovery in craniotomy surgery patients, though the underlying mechanism is not detailed.
Precedex is being developed by The Cooper Companies, Inc., which trades on the New York Stock Exchange under the ticker symbol COO. The company is conducting clinical research on the drug for use in craniotomy surgery.
Precedex is in Phase 3 clinical development. A Phase 3 trial has been completed, which evaluated the drug in patients undergoing craniotomy surgery. The drug is investigational and has not been approved for this use.
Precedex has been studied in one clinical trial, identified as NCT00848991. This Phase 3 trial compared Precedex with propofol for emergence and recovery in patients having craniotomy surgery. The trial was completed and enrolled 15 participants.
No, Precedex is not the same as propofol. Precedex is a separate drug being studied in comparison to propofol in a clinical trial for craniotomy surgery. The trial was designed to compare the two drugs for emergence and recovery outcomes.